24 completed, 7 recruiting, 6 terminated, 5 unknown. 13 Phase 2, 13 Phase 4, 12 Phase 3, 5 Phase 1, 4 Not applicable.
Follow Zoledronate: new trials by email Literature Review of Zoledronate trials Research Report on Zoledronate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors Zoledronate - Hematopoietic Stem Cell Transplantation | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-07-17 | 2026-08-10 |
| Step-down Therapy After Long-term Osteoporosis Treatment zoledronate, Denosumab De-escalation - Osteoporosis | Phase 4 | Recruiting | National Taiwan University Hospital | 44 | 2026-01-01 | 2025-12-15 |
| Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism Zoledronic acid 4 mg, Natriumklorid 9 mg/ml, Fresenius Kabi - Primary Hyperparathyroidism | Phase 4 | Recruiting | University of Aarhus | 140 | 2025-03-01 | 2026-10-01 |
| Sequential Therapies After Osteoanabolic Treatment Zoledronate, Denosumab, Teriparatide - Osteoporosis, Postmenopausal | Recruiting | 424 General Military Hospital | 150 | 2023-11-25 | 2026-07-22 | |
| The Optimised Use of Romozosumab Study Romosozumab, Zoledronate - Osteoporosis | Phase 4 | Recruiting | University of Aarhus | 270 | 2023-10-02 | 2026-07-02 |
| Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) Zoledronate, Placebo - Osteoporosis, Postmenopausal | Phase 4 | Active not recruiting | Aarhus University Hospital | 200 | 2023-05-10 | 2025-10-02 |
| The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients Zoledronate - Hip Fractures, Pneumonia | Phase 4 | Unknown | The University of Hong Kong | 2692 | 2022-12-05 | 2024-02-20 |
| A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study) Zoledronic acid, once, Zoledronic acid, twice - Osteoporosis | Phase 4 | Completed | Yonsei University | 114 | 2022-02-11 | 2025-03-07 |
| The Optimal Sequential Therapy After Long Term Denosumab Treatment zoledronate, Alendronate and Zoledronate - Osteoporosis | Phase 4 | Completed | National Taiwan University Hospital | 44 | 2022-01-10 | 2025-11-19 |
| Zoledronate Early to Hip Fracture Patients - Safe and Effective? Zoledronic Acid 5Mg/Bag 100Ml Inj, sodium chloride - Hip Fractures, Osteoporosis | Phase 4 | Completed | Lene Bergendal Solberg | 228 | 2021-12-15 | 2026-08-12 |
| Denosumab vs Zoledronate After Vertebroplasty Denosumab Injection, Zoledronate - Denosumab Allergy, Zoledronic Acid Allergy | Phase 4 | Completed | Shenzhen People's Hospital | 75 | 2021-01-12 | 2023-01-18 |
| Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer Bone modifying agent - Breast Cancer, Castration-resistant Prostate Cancer | Phase 4 | Active not recruiting | Ottawa Hospital Research Institute | 240 | 2020-10-09 | 2026-07-21 |
| Denosumab vs Zoledronate After Lumbar Fusion Denosumab 60 mg/ml [Prolia], Zoledronate - Osteopenia, Lumbar Spondylolisthesis | Phase 3 | Unknown | Shenzhen People's Hospital | 100 | 2020-01-15 | 2023-02-21 |
| Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) Zoledronate - Early-stage Breast Cancer | Phase 4 | Completed | Ottawa Hospital Research Institute | 211 | 2018-10-31 | 2026-07-07 |
| Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone Zoledronic Acid - Giant Cell Tumor of Bone | Phase 3 | Recruiting | St. Louis University | 120 | 2018-05-03 | 2026-04-22 |
| Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer Zoledronate, Atorvastatin 80mg, Standard neoadjuvant cht - Triple Negative Breast Cancer | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 54 | 2018-03-05 | 2023-10-19 |
| Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients Zoledronic Acid, Enzalutamide - Prostate Cancer, Bone Metastases | Phase 2 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 126 | 2017-12-01 | 2024-08-01 |
| Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis Zoledronic Acid - Osteoporosis | Phase 4 | Completed | Aarhus University Hospital | 61 | 2017-03-13 | 2021-02-21 |
| 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases Pamidronate, Denosumab, Zoledronate - Breast Cancer, Prostate Cancer | Phase 4 | Completed | Ottawa Hospital Research Institute | 263 | 2016-08-01 | 2020-12-02 |
| Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid zoledronic acid, pharmacological study - Malignant Neoplasm, Musculoskeletal Complications | Not applicable | Withdrawn | University of Southern California | 2016-06-01 | 2017-04-11 |
Showing 20 of 46. Sign in to see all of them.
Breast Neoplasms (14) · Osteoporosis (11) · Bone Diseases, Metabolic (6) · Prostatic Neoplasms (6) · Neoplasm Metastasis (4) · Hip Fractures (2) · Humoral Hypercalcemia Of Malignancy (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Osteoporosis, Postmenopausal (2) · Osteosarcoma (2) · Arthropathy, Neurogenic (1) · Breast Neoplasms, Male (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Intraductal, Noninfiltrating (1)
M.D. Anderson Cancer Center (4) · Ottawa Hospital Research Institute (3) · Aarhus University Hospital (2) · Mario Negri Institute for Pharmacological Research (2) · National Taiwan University Hospital (2) · Novartis Pharmaceuticals (2) · Shenzhen People's Hospital (2) · University of Aarhus (2) · University of California, San Francisco (2) · University of Wisconsin, Madison (2) · 424 General Military Hospital (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Oncology Group (1) · City of Hope Medical Center (1)
United States (21) · Canada (7) · Denmark (4) · Italy (4) · China (3) · Puerto Rico (3) · India (2) · Taiwan (2) · Australia (1) · Austria (1) · Germany (1) · Greece (1) · Hong Kong (1) · Norway (1) · South Korea (1)
Alberto Zambelli, MD (2) · Mark Clemons, MD (2) · Shi-Ming Tu, MD (2) · Alfredo Berruti, MD (1) · Anil Bhansali, DM (1) · Bente L Langdahl, MD PhD DMSc (1) · Bente Langdahl, MD, Professor, DMSc, PhD (1) · Bente Langdahl, MD, Professor, DMSc, PhD, (1) · Celia Rodd, MD FRCPC (1) · Christian Capitini, MD (1) · Colleen A. Lawton, MD (1) · Daniel Mulkerin, MD (1) · David C. Smith, MD (1) · Dawn Hershman, MD (1)
PMID 38979716, PMID 40446745, PMID 18777528, PMID 19455472, PMID 21958521, PMID 22894553, PMID 23096187, PMID 23276888, PMID 23664013, PMID 24258798, PMID 24332514, PMID 24510426, PMID 24590644, PMID 24772219, PMID 24881730, PMID 25687533, PMID 25985882, PMID 28125763, PMID 28274254, PMID 31401903, PMID 32459005, PMID 33813753, PMID 34068083, PMID 34748565, PMID 42035902
2005 (1), 2015 (1), 2016 (1), 2017 (1), 2023 (1), N01CM17104 (1), P30CA014089 (1), R21AI058756 (1), U10CA037429 (1), U10CA045809 (1)